{"id":5892,"date":"2024-12-05T07:10:42","date_gmt":"2024-12-05T13:10:42","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5892"},"modified":"2025-06-27T08:31:14","modified_gmt":"2025-06-27T13:31:14","slug":"ray-kaczmarek-joins-nanoscope","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/12\/05\/ray-kaczmarek-joins-nanoscope\/","title":{"rendered":"El veterano de la industria y experto en fabricaci\u00f3n de terapias gen\u00e9ticas, Ray Kaczmarek, se une a Nanoscope como director t\u00e9cnico y de fabricaci\u00f3n"},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\"><\/div>\n<\/div>\n<\/div>\n<\/div>\n<article class=\"news-release inline-gallery-template\">\n<section class=\"release-body container\">\n<div class=\"row\">\n<div class=\"col-lg-10 col-lg-offset-1\">\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">DALLAS<\/span><\/span>,\u00a0<span class=\"legendSpanClass\"><span class=\"xn-chron\">5 de diciembre de 2024<\/span><\/span>\u00a0\u2014 <a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4318063-1&h=3734763871&u=https%3A%2F%2Fnanostherapeutics.com%2F&a=Nanoscope+Therapeutics+Inc.\" target=\"_blank\" rel=\"nofollow noopener\">Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda cl\u00ednica en etapa avanzada que desarrolla terapias gen\u00e9ticas para enfermedades hereditarias de la retina y atrofia geogr\u00e1fica (AG), anunci\u00f3 hoy que\u00a0<span class=\"xn-person\">Ray Kaczmarek<\/span>\u00a0se ha incorporado a la empresa como director de tecnolog\u00eda y fabricaci\u00f3n. El Sr. Kaczmarek es un reconocido experto en fabricaci\u00f3n de terapias gen\u00e9ticas con d\u00e9cadas de experiencia en la direcci\u00f3n de operaciones, tecnolog\u00eda y estrategias de suministro comercial en empresas farmac\u00e9uticas y biotecnol\u00f3gicas.<\/p>\n<p>\u201cRay aporta una vasta experiencia en la creaci\u00f3n y el mantenimiento de programas de fabricaci\u00f3n de terapia g\u00e9nica. Su liderazgo operativo ser\u00e1 crucial para desarrollar el suministro comercial de nuestras futuras terapias a medida que avanzamos hacia su posible comercializaci\u00f3n\u201d, dijo\u00a0<span class=\"xn-person\">Sulagna Bhattacharya<\/span>, Cofundador y director ejecutivo de Nanoscope.<\/p>\n<p>El Sr. Kaczmarek tiene una amplia trayectoria de liderazgo ejecutivo y experiencia operativa en la industria de fabricaci\u00f3n de terapias g\u00e9nicas. M\u00e1s recientemente, se desempe\u00f1\u00f3 como director ejecutivo de Genezen, una organizaci\u00f3n de desarrollo y fabricaci\u00f3n por contrato (CDMO) especializada en el desarrollo de procesos de vectores virales, fabricaci\u00f3n GMP y servicios anal\u00edticos. Antes de Genezen, el Sr. Kaczmarek se desempe\u00f1\u00f3 como vicepresidente de operaciones GMP en TriLink Biotechnologies, parte de Maravai Lifesciences, una CDMO especializada en la s\u00edntesis de \u00e1cidos nucleicos, reactivos de protecci\u00f3n GMP, pl\u00e1smidos y oligonucle\u00f3tidos. El Sr. Kaczmarek tambi\u00e9n se desempe\u00f1\u00f3 como vicepresidente de operaciones de fabricaci\u00f3n y cadena de suministro en Pacira Biosciences, un proveedor l\u00edder de soluciones de salud regenerativa y manejo del dolor sin opioides y, antes de eso, fue presidente de Nitto Avecia, una CDMO especializada en soluciones integrales para programas de oligonucle\u00f3tidos. El Sr. Kaczmarek es graduado de la Universidad de\u00a0<span class=\"xn-org\">Universidad Tecnol\u00f3gica de Virginia<\/span>\u00a0y un orgulloso veterano del Ej\u00e9rcito de los Estados Unidos.<\/p>\n<p>\u201cNanoscope ha llegado a un punto crucial en su misi\u00f3n de llevar al mercado productos de terapia g\u00e9nica transformadores\u201d, declar\u00f3 el Sr. Kaczmarek. \u201cMe entusiasma aportar mi experiencia a los programas de Nanoscope y espero liderar el desarrollo de la fabricaci\u00f3n comercial de productos para garantizar que Nanoscope est\u00e9 preparada para ofrecer estos tratamientos tan necesarios a los pacientes\u201d.\u201d<\/p>\n<p><b>Acerca de Nanoscope Therapeutics, Inc.<br class=\"dnr\" \/><\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas que restauran la visi\u00f3n y que no dependen de los genes para los millones de pacientes que han perdido la visi\u00f3n a causa de enfermedades degenerativas de la retina, para las que no existe cura. Tras los resultados positivos de final de estudio del ensayo cl\u00ednico RESTORE de fase 2b, multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo para la RP (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>), la compa\u00f1\u00eda anunci\u00f3 su plan de iniciar un\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/\" target=\"_blank\" rel=\"nofollow noopener\">Presentaci\u00f3n de BLA para MCO-010 para tratar RP<\/a>\u00a0en el primer trimestre de 2025. La empresa ha completado el ensayo STARLIGHT de fase 2 de la terapia MCO-010 en pacientes con Stargardt (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>) y planea iniciar una\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/\" target=\"_blank\" rel=\"nofollow noopener\">Ensayo de registro de fase 3<\/a>\u00a0en el primer trimestre de 2025. MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para RP como para Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la atrofia geogr\u00e1fica.<\/p>\n<p><b>Contacto de inversores:<\/b><br class=\"dnr\" \/>Socios Argot<br class=\"dnr\" \/>212-600-1902<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p>\n<p>FUENTE Terap\u00e9utica del Nanoscopio<\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"<p>DALLAS,\u00a0Dec. 5, 2024\u00a0\u2014 Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and geographic atrophy (GA), today announced that\u00a0Ray Kaczmarek\u00a0has joined the company as Chief Technology and Manufacturing Officer. Mr. Kaczmarek is a recognized expert in gene therapy manufacturing with decades of experience leading operations, technology, and commercial supply [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5895,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5892","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Industry Veteran and Gene Therapy Manufacturing Expert, Ray Kaczmarek, Joins Nanoscope as Chief Technical and Manufacturing Officer - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/12\/05\/ray-kaczmarek-joins-nanoscope\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Industry Veteran and Gene Therapy Manufacturing Expert, Ray Kaczmarek, Joins Nanoscope as Chief Technical and Manufacturing Officer - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/12\/05\/ray-kaczmarek-joins-nanoscope\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-05T13:10:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T13:31:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/12\/NSCOPE_LI_Kaczmarke_V3FIN.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/12\/NSCOPE_LI_Kaczmarke_V3FIN.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/05\\\/ray-kaczmarek-joins-nanoscope\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/05\\\/ray-kaczmarek-joins-nanoscope\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Industry Veteran and Gene Therapy Manufacturing Expert, Ray Kaczmarek, Joins Nanoscope as Chief Technical and Manufacturing Officer\",\"datePublished\":\"2024-12-05T13:10:42+00:00\",\"dateModified\":\"2025-06-27T13:31:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/05\\\/ray-kaczmarek-joins-nanoscope\\\/\"},\"wordCount\":450,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/05\\\/ray-kaczmarek-joins-nanoscope\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/NSCOPE_LI_Kaczmarke_V3FIN.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/05\\\/ray-kaczmarek-joins-nanoscope\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/05\\\/ray-kaczmarek-joins-nanoscope\\\/\",\"name\":\"Industry Veteran and Gene Therapy Manufacturing Expert, Ray Kaczmarek, Joins Nanoscope as Chief Technical and Manufacturing Officer - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/05\\\/ray-kaczmarek-joins-nanoscope\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/05\\\/ray-kaczmarek-joins-nanoscope\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/NSCOPE_LI_Kaczmarke_V3FIN.jpg\",\"datePublished\":\"2024-12-05T13:10:42+00:00\",\"dateModified\":\"2025-06-27T13:31:14+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/05\\\/ray-kaczmarek-joins-nanoscope\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/05\\\/ray-kaczmarek-joins-nanoscope\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/05\\\/ray-kaczmarek-joins-nanoscope\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/NSCOPE_LI_Kaczmarke_V3FIN.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/NSCOPE_LI_Kaczmarke_V3FIN.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/05\\\/ray-kaczmarek-joins-nanoscope\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Industry Veteran and Gene Therapy Manufacturing Expert, Ray Kaczmarek, Joins Nanoscope as Chief Technical and Manufacturing Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ray Kaczmarek, veterano de la industria y experto en la fabricaci\u00f3n de terapias g\u00e9nicas, se une a Nanoscope como Director T\u00e9cnico y de Fabricaci\u00f3n de Nanoscope Therapeutics.","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/12\/05\/ray-kaczmarek-joins-nanoscope\/","og_locale":"es_MX","og_type":"article","og_title":"Industry Veteran and Gene Therapy Manufacturing Expert, Ray Kaczmarek, Joins Nanoscope as Chief Technical and Manufacturing Officer - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/12\/05\/ray-kaczmarek-joins-nanoscope\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-12-05T13:10:42+00:00","article_modified_time":"2025-06-27T13:31:14+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/12\/NSCOPE_LI_Kaczmarke_V3FIN.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/12\/NSCOPE_LI_Kaczmarke_V3FIN.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/12\/05\/ray-kaczmarek-joins-nanoscope\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/12\/05\/ray-kaczmarek-joins-nanoscope\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Industry Veteran and Gene Therapy Manufacturing Expert, Ray Kaczmarek, Joins Nanoscope as Chief Technical and Manufacturing Officer","datePublished":"2024-12-05T13:10:42+00:00","dateModified":"2025-06-27T13:31:14+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/12\/05\/ray-kaczmarek-joins-nanoscope\/"},"wordCount":450,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/12\/05\/ray-kaczmarek-joins-nanoscope\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/12\/NSCOPE_LI_Kaczmarke_V3FIN.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/12\/05\/ray-kaczmarek-joins-nanoscope\/","url":"https:\/\/nanostherapeutics.com\/2024\/12\/05\/ray-kaczmarek-joins-nanoscope\/","name":"Ray Kaczmarek, veterano de la industria y experto en la fabricaci\u00f3n de terapias g\u00e9nicas, se une a Nanoscope como Director T\u00e9cnico y de Fabricaci\u00f3n de Nanoscope Therapeutics.","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/12\/05\/ray-kaczmarek-joins-nanoscope\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/12\/05\/ray-kaczmarek-joins-nanoscope\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/12\/NSCOPE_LI_Kaczmarke_V3FIN.jpg","datePublished":"2024-12-05T13:10:42+00:00","dateModified":"2025-06-27T13:31:14+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/12\/05\/ray-kaczmarek-joins-nanoscope\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/12\/05\/ray-kaczmarek-joins-nanoscope\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/12\/05\/ray-kaczmarek-joins-nanoscope\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/12\/NSCOPE_LI_Kaczmarke_V3FIN.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/12\/NSCOPE_LI_Kaczmarke_V3FIN.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/12\/05\/ray-kaczmarek-joins-nanoscope\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Industry Veteran and Gene Therapy Manufacturing Expert, Ray Kaczmarek, Joins Nanoscope as Chief Technical and Manufacturing Officer"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5892","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5892"}],"version-history":[{"count":5,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5892\/revisions"}],"predecessor-version":[{"id":9008,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5892\/revisions\/9008"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5895"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5892"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5892"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5892"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}